A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

NCT03781934 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Intrahepatic Cholangiocarcinoma
Liver Metastases

Interventions

DRUG: MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
DRUG: MIV-818 (fostroxacitabine bralpamide) + lenvatinib

Sponsor

Medivir